Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8626256rdf:typepubmed:Citationlld:pubmed
pubmed-article:8626256lifeskim:mentionsumls-concept:C0031809lld:lifeskim
pubmed-article:8626256lifeskim:mentionsumls-concept:C0007732lld:lifeskim
pubmed-article:8626256lifeskim:mentionsumls-concept:C0279516lld:lifeskim
pubmed-article:8626256lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:8626256lifeskim:mentionsumls-concept:C0022877lld:lifeskim
pubmed-article:8626256pubmed:issue5lld:pubmed
pubmed-article:8626256pubmed:dateCreated1996-6-26lld:pubmed
pubmed-article:8626256pubmed:abstractTextZwitterionic 7-methoxyimino cephalosporins (cefpirome, cefepime, cefclidin, DQ2556, FK037 and SCE2787) possess a variable substitution at C3 which contains a quarternary nitrogen. These cephalosporins display low affinities for Class I beta-lactamase and rapid penetration through the outer membrane of Gram-negative bacilli, so that an increased number of periplasmic beta-lactam molecules interact with PBP's per unit of time. As a consequence, the new zitterionic compounds remain active against some, but not all, ceftazidime-resistant Enterobacteriaceae producing high levels of Class I beta-lactamase or Bush type 2b beta-lactamases. Antipseudomonas activities are generally similar to that of ceftazidime except that cefclidin is more active. The new zwitterionic compounds, especially cefpirome and FK037, express greater antistaphylococcal potency than does ceftazidime. A variety of animal models including meningitis and endocarditis have confirmed the potential of these compounds in-vivo. On the basis of structural and antibacterial characteristics, the expression 'forth generation' is acceptable to describe the zwitterionic 7-methoxyimino cephalosporins.lld:pubmed
pubmed-article:8626256pubmed:languageenglld:pubmed
pubmed-article:8626256pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8626256pubmed:citationSubsetIMlld:pubmed
pubmed-article:8626256pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8626256pubmed:statusMEDLINElld:pubmed
pubmed-article:8626256pubmed:monthNovlld:pubmed
pubmed-article:8626256pubmed:issn0305-7453lld:pubmed
pubmed-article:8626256pubmed:authorpubmed-author:WilsonWWlld:pubmed
pubmed-article:8626256pubmed:authorpubmed-author:NeuHHlld:pubmed
pubmed-article:8626256pubmed:authorpubmed-author:PechèreJ CJClld:pubmed
pubmed-article:8626256pubmed:issnTypePrintlld:pubmed
pubmed-article:8626256pubmed:volume36lld:pubmed
pubmed-article:8626256pubmed:ownerNLMlld:pubmed
pubmed-article:8626256pubmed:authorsCompleteYlld:pubmed
pubmed-article:8626256pubmed:pagination757-71lld:pubmed
pubmed-article:8626256pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:8626256pubmed:meshHeadingpubmed-meshheading:8626256-...lld:pubmed
pubmed-article:8626256pubmed:meshHeadingpubmed-meshheading:8626256-...lld:pubmed
pubmed-article:8626256pubmed:meshHeadingpubmed-meshheading:8626256-...lld:pubmed
pubmed-article:8626256pubmed:year1995lld:pubmed
pubmed-article:8626256pubmed:articleTitleLaboratory assessment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins.lld:pubmed
pubmed-article:8626256pubmed:affiliationDepartment of Genetics and Microbiology, University of Geneva, Switzerland.lld:pubmed
pubmed-article:8626256pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8626256pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8626256lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8626256lld:pubmed